EP4630158A1 - Adsorbant et ses procédés de fabrication et d'utilisation - Google Patents

Adsorbant et ses procédés de fabrication et d'utilisation

Info

Publication number
EP4630158A1
EP4630158A1 EP23825080.7A EP23825080A EP4630158A1 EP 4630158 A1 EP4630158 A1 EP 4630158A1 EP 23825080 A EP23825080 A EP 23825080A EP 4630158 A1 EP4630158 A1 EP 4630158A1
Authority
EP
European Patent Office
Prior art keywords
kda
adsorbent
protein
biological product
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23825080.7A
Other languages
German (de)
English (en)
Inventor
Chris Sadler
Ben BEACOM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astrea UK Services Ltd
Original Assignee
Astrea UK Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrea UK Services Ltd filed Critical Astrea UK Services Ltd
Publication of EP4630158A1 publication Critical patent/EP4630158A1/fr
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/24—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the treatment of the fractions to be distributed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206—Organic carriers, supports or substrates
    • B01J20/3208—Polymeric carriers, supports or substrates
    • B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3255—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes

Definitions

  • the present invention relates to an adsorbent for the capture and removal of impurities from a biological product.
  • the invention also encompasses compounds which may be used to produce the adsorbent, methods of producing the adsorbent, uses of the adsorbent and methods of using the adsorbent to capture and remove target impurities. Removal of endogenous and process-related impurities is a particular challenge in the manufacture of a wide array of biotherapeutic targets including but not limited to recombinant proteins, viral vectors, extracellular vesicles and nucleic acids.
  • HCPs host cell proteins
  • endotoxin host cell DNA
  • product and process related impurities are necessary due to strict regulation of the allowable limits of these impurities to ensure product efficacy and safety.
  • host cell proteins can be especially difficult to remove even when using a purification process involving a highly selective affinity capture step.
  • mAbs monoclonal antibodies
  • mAb biologics have been released for a number of indications including cancer treatment, rheumatology, hematology and infectious diseases, and a strong pipeline of new mAb products are currently in development [2].
  • the dominant method of production of recombinant mAbs is by expression from mammalian cell systems, most notably Chinese hamster ovary (CHO) cells.
  • CHO Chinese hamster ovary
  • most downstream processes for mAb purification utilize Protein A, an affinity chromatography step which involves a ligand with specific affinity to the fragment crystallizable (Fc) region of the antibody protein.
  • the eluate from the protein A column is further purified in polishing steps which often include multiple ion exchange and hydrophobic interaction chromatography stages.
  • HCPs represent a broad array of peptide or protein biomolecules, potentially made up of thousands of individual species. HCPs are intrinsically present in the manufacture of cell-derived products. For example, in the production of mAbs, HCP concentration in the post Protein A eluate typically range from 200 to 3000 ppm, but levels as high as 70,000 ppm have been reported [6]. The profile of HCP impurities can vary significantly depending on the expression system and upstream process parameters.
  • AEX anion exchange chromatography
  • HMW aggregates high molecular weight aggregates
  • HIC hydrophobic interaction chromatography
  • AAV Adeno Associated Virus
  • an adsorbent having formula (I): , wherein: R 1 and R 2 are each independently a C 1-5 alkyl or a C 3-6 cycloalkyl; L is absent or is a linker; and A is a substrate.
  • the adsorbent of the first aspect can be used to selectively remove HCPs and other impurities from a feedstock without detrimentally affecting yield of a target biological product. Additionally, the adsorbent retains functionality at relatively high conductivity load conditions. Furthermore, the adsorbent is stable to a wide range of pH conditions including 0.5 M NaOH typically used for cleaning and sanitization. Furthermore, the adsorbent can be manufactured sustainably with minimized use of organic solvents and raw materials.
  • R 1 and R 2 may be the same or different. In some embodiments, R 1 and R 2 may be the same. In some embodiments, at least one of R 1 and R 2 is a C 1-5 alkyl.
  • the alkyl may be a straight chain or branched alkyl.
  • the alkyl is a branched alkyl.
  • at least one of R 1 and R 2 is a C 2-5 alkyl or a C 3-4 alkyl.
  • at least one of R 1 and R 2 is a C 4 alkyl.
  • At least one of R 1 and R 2 may be isobutyl.
  • R 1 and R 2 are both isobutyl.
  • the adsorbent may have formula (Ia): H H N N N
  • at least one of R 1 and R 2 is a C 3-6 cycloalkyl.
  • R 1 and R 2 is a C 4-6 cycloalkyl or a C 5-6 cycloalkyl. Accordingly, at least one of R 1 and R 2 may be cyclohexyl. In some embodiments, R 1 and R 2 are both cyclohexyl. Accordingly, the adsorbent may have formula (Ib): Suitable substrate be known in the art. For example, L may be or comprise an amino group, an ether group, a thioether group or an optionally substituted alkyl group optionally interrupted by one or more heteroatoms.
  • L may be: *–L 1 –L 2 –L 3 –L 4 – wherein L 1 and L 3 are independently absent or an optionally substituted C 1-24 alkylene, an optionally substituted C 2-24 alkenylene or an optionally substituted C 2-24 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is optionally interrupted by one or more heteroatoms; L 2 and L 4 are independently absent or NR 4 , O, S, COO or CONR 4 ; R 4 is H, an optionally substituted C 1-12 alkyl, an optionally substituted C 1-12 alkenyl or an optionally substituted C 1-12 alkynyl; and an asterisk indicates the point of attachment to A, or a residue thereof.
  • each alkylene, alkenylene, alkynylene, alkyl, alkenyl and alkynyl may be straight or branched.
  • the or each alkylene, alkenylene, alkynylene, alkyl, alkenyl and alkynyl may be unsubstituted or substituted with one or more of halogen, OH, SH, COOH, NH 2 and/or oxo.
  • each alkylene, alkenylene, alkynylene, alkyl, alkenyl and alkynyl is unsubstituted or substituted with one or more of OH and/or oxo.
  • the or each heteroatom may be selected from the group consisting of NR 5 , O and S, wherein R 5 is H, an optionally substituted C 1-12 alkyl, an optionally substituted C 1-12 alkenyl or an optionally substituted C 1-12 alkynyl.
  • L 2 is NR 4 .
  • R 4 may be H.
  • L 2 may be O.
  • L 1 is an optionally substituted C 1-12 alkylene, an optionally substituted C 2-12 alkenylene or an optionally substituted C 2-12 alkynylene.
  • L 1 may be an optionally substituted C 1-6 alkylene, an optionally substituted C 2-6 alkenylene or an optionally substituted C 2-6 alkynylene.
  • L 1 is an optionally substituted C 1-3 alkylene, an optionally substituted C 2-3 alkenylene or an optionally substituted C 2-3 alkynylene.
  • the alkylene, alkenylene or alkynylene may be unsubsituted or substituted with OH. Accordingly, L 1 may , where an asterisk indicates the point of attachment to A. Alternatively, L 1 may be absent. Accordingly, * –L 1 –L 2 – may asterisk indicates the point In some embodiments, L 3 may be absent. In some embodiments, L 4 may be absent.
  • L 4 is also absent.
  • L 3 and/or L 4 may be present.
  • L 3 may be an optionally substituted C 1-12 alkylene, an optionally substituted C 2-12 alkenylene or an optionally substituted C 2-12 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is optionally interrupted by one or more heteroatoms.
  • the alkylene, alkenylene or alkynylene may be unsubsituted or substituted with OH or oxo.
  • the or each heteroatom may be selected from the group consisting of NR 5 or O.
  • R 5 is preferably H.
  • L 3 may be an optionally substituted C 2-8 alkylene, an optionally substituted C 2-8 alkenylene or an optionally substituted C 2-8 alkynylene. Accordingly, L 3 may .
  • L 3 may .
  • an may an C 4-12 alkylene, an optionally substituted C 4-12 alkenylene or an optionally substituted C 4-12 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is optionally interrupted by one or more heteroatoms.
  • L 3 may be an optionally substituted C 6-12 alkylene, an optionally substituted C 6-12 alkenylene or an optionally substituted C 6-12 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is interrupted by one or more heteroatoms.
  • L 3 may be an optionally substituted C 7-10 alkylene, an optionally substituted C 7-10 alkenylene or an optionally substituted C 7-10 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is interrupted by one or more heteroatoms. Accordingly, L 3 may or .
  • L 4 is NR 4 .
  • R 4 may be H. .
  • the substrate may be a solid support.
  • the solid support may be selected from the group consisting of a controlled pore glass, a magnetic controlled pore glass, a silica- containing particle, a polymer, a magnetic polymer and a controlled pore glass grafted with a polymer.
  • the solid support may be or comprise a polymer.
  • the polymer may be or comprise a natural polymer or a synthetic polymer.
  • the polymer may be or comprise a polysaccharide, a polymethacrylate, a polymer of styrene, a copolymer of styrene and divinylbenzene, a copolymer of styrene and divinylbenzene grafted with polyethyleneglycol or a copolymer of dimethylacrylamide and N,N,- bisacryloylethylenediamine.
  • the polysaccharide may be or comprise agarose, cellulose, hemicellulose, dextran, carrageenan or chitin.
  • the substrate may be a fibre, a nanofibre, a fibre mat, a nanofibre mat, a membrane, a solid bead, a porous bead, a monolith or a solid gel.
  • a compound of formula (II) or (III) wherein R 1 , R 2 , L 3 and L 4 are as defined in relation to the first aspect; R 3 is a reactive leaving group; and R 6 is a reactive nucleophile or a reactive electrophile.
  • a compound of formula (II) or (III) may be used to produce the adsorbent of the first aspect.
  • R 3 may be a halogen.
  • R 3 may be chlorine, bromine or iodine. In some embodiments, R 3 is chlorine.
  • R 6 may be NR 7 R 8 , OR 9 or SR 9 , where R 7 and R 8 are H, an optionally substituted C 1-12 alkyl, an optionally substituted C 1- 12 alkenyl or an optionally substituted C 1-12 alkynyl and R 9 is H.
  • R 7 is H.
  • R 8 is H.
  • R 6 is NR 7 R 8 .
  • the attachment of a compound of formula (II) or formula (III) to a substrate (A), via a linker (L), may be achieved by use of an activating agent to introduce chemically reactive groups onto the surface of the substrate (A).
  • activating agents include but are not limited to epichlorohydrin, 1,4- butanedioldiglycidylether, allyl bromide, allylglycidylether, sodium periodate, cyanogen bromide or divinylsulphone.
  • an activated substrate comprises a primary amine group or a carboxyl group
  • attachment to a compound of formula (II) may be facilitated by use of reagents that promote amide bond formation including but not limited to N- hydroxysuccinimide or a carbodiimide.
  • a method of producing an adsorbent comprising either: - contacting a first activated substrate and cyanuric chloride to provide a dichlorotriazine activated substrate; and - contacting the dichlorotriazine activated substrate and a compound of formula (IV): NH 2 R 1 (IV) , wherein R 1 is as defined in relation to the first aspect; to thereby provide the adsorbent; or - contacting a first activated substrate and provided a compound of formula (II) or (III): H H R 1 N N N R 2 , and aspects to The method may provide the adsorbent of the first aspect.
  • the dichlorotriazine activated substrate may be understood to be a compound of (V): wherein A and L are as defined in to first aspect.
  • the first activated substrate may be understood to be a substrate which comprises a reactive group. Accordingly, the first activated substrate may have formula (VI): A–L 1 –L 2 –L 3 –R 10 (VI) , wherein R 10 is NHR 4 , OH or SH; and L 1 , L 2 , L 3 , R 4 and A are as defined in relation to the first aspect.
  • the first activated substrate and cyanuric chloride or the compound of formula (II) or (III) may be contacted at a molar ratio of between 10:1 and 20:1, between 5:1 and 1:10, between 3:1 and 1:5, between 2:1 and 1:3, between 1:1 and 1:2, between 1:1.2 and 1:1.75 or between 1:1.3 and 1:1.5.
  • the molar ratio may be understood to be a ratio of the moles of a reactive group (e.g. R 6 ) on the substrate to moles of cyanuric chloride.
  • the first activated substrate and cyanuric chloride or the compound of formula (II) or (III) may be contacted at a temperature between -100 and 100°C, between -75 and 75°C, between -50 and 50°C, between -30 and 30°C, between -20 and 20°C, between - 10 and 10°C, between -5 and 7.5°C or between 0 and 4°C.
  • the first activated substrate and cyanuric chloride or the compound of formula (II) or (III) may be contacted for at least 1 minute, at least 5 minutes, at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes or at least 50 minutes.
  • the first activated substrate and cyanuric chloride may be contacted for between 1 minute and 72 hours, between 5 minutes and 24 hours, between 10 minutes and 12 hours, between 20 minutes and 6 hours, between 30 minutes and 2 hours, between 40 and 90 minutes or between 50 and 70 minutes.
  • the first activated substrate and cyanuric chloride or the compound of formula (II) or (III) may be contacted in the presence of a first solvent.
  • the first solvent may be or comprise water and/or an organic solvent.
  • the organic solvent may be or comprise acetone, tetrahydrofuran, dioxane or combinations thereof.
  • the first solvent may comprise a combination of water and the organic solvent.
  • the first solvent may comprise water and the organic solvent at a volumetric ratio of between 1:10 and 10:1, between 1:5 and 5:1, between 1:3 and 3:1, between 1:2 and 2:1 or between 1:1.5 and 1.5:1.
  • the first activated substrate and cyanuric chloride or the compound of formula (II) or (III) may be contacted in the presence of a pH buffer.
  • the pH buffer may be a phosphate, preferably potassium phosphate.
  • the pH buffer may be present at a concentration of between 0.01 and 10 M, between 0.02 and 5 M, between 0.04 and 2 M, between 0.06 and 1 M, between 0.08 and 0.75 M, between 0.1 and 0.5 M or between 0.2 and 0.3 M.
  • the dichlorotriazine activated substrate and compound of formula (IV) may be contacted at a temperature between 0 and 200°C, between 10 and 150°C, between 20 and 125°C, between 20 and 100°C, between 30 and 90°C, between 40 and 80°C, between 50 and 70°C or between 55 and 65°C.
  • the dichlorotriazine activated substrate and compound of formula (IV) may be contacted for at least 1 minute, at least 5 minutes, at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours or at least 6 hours.
  • the first activated substrate and cyanuric chloride may be contacted for between 1 minute and 4 weeks, between 30 minutes and a week, between 1 and 72 hours, between 2 and 48 hours, between 3 and 24 hours, between 4 and 12 hours, between 5 and 8 hours or between 6 and 7 hours.
  • the dichlorotriazine activated substrate and compound of formula (IV) may be contacted in a second solvent.
  • the second solvent may be or comprise water and/or an organic solvent.
  • the organic solvent may be or comprise an alcohol or acetone.
  • the alcohol may be or comprise ethanol or isopropyl alcohol (IPA).
  • the dichlorotriazine activated substrate and the compound of formula (IV) may be contacted in a weight ratio of between 5,000:1 and 1:1, between 2,000:1 and 5:1, between 1,000:1 and 10:1, between 1,000:2 and 100:5, between 1,000:4 and 100:2 or between 1,000:6 and 100:1.
  • the dichlorotriazine activated substrate and the compound of formula (IV) may be contacted in a molar ratio of between 3:1 and 1:50, between 2:1 and 1:20, between 1:1 and 1:15, between 1:2 and 1:10, between 1:3 and 1:8 or between 1:4 and 1:6.
  • the molar ratio may be understood to be the ratio of the number of moles of the dichlorotriazine groups on the substrate to the number of moles of the compound of formula (IV).
  • the method may comprise contacting a pre-activated substrate and ammonia or a diamine to provide the first activated substrate.
  • the pre-activated substrate may be an epoxy-activated substrate, an allyl activated substrate or an oxidised substrate.
  • An epoxy-activated substrate may be understood to be a substrate which comprises an epoxy group.
  • An allyl activated substrate may be understood to be a substrate which comprises an allyl group.
  • a oxidised substrate may be understood to be a substrate which has been oxidised.
  • the diamine may be a compound of formula (VII): R 11 R 12 N-L 5 -NR 13 R 14 (VII) wherein L 5 is an optionally substituted C 1-24 alkylene, an optionally substituted C 2-24 alkenylene or an optionally substituted C 2-24 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is optionally interrupted by one or more heteroatoms; and R 11 , R 12 , R 13 and R 14 are independently H, an optionally substituted C 1-12 alkyl, an optionally substituted C 1-12 alkenyl or an optionally substituted C 1-12 alkynyl.
  • L 5 is an optionally substituted C 3-12 alkylene, an optionally substituted C 3-12 alkenylene or an optionally substituted C 3-12 alkynylene. More preferably, L 5 is an optionally substituted C 4-8 alkylene, an optionally substituted C 4-8 alkenylene or an optionally substituted C 4-8 alkynylene.
  • R 11 , R 12 , R 13 and R 14 may independently be H, an optionally substituted C 1-6 alkyl, an optionally substituted C 1-6 alkenyl or an optionally substituted C 1-6 alkynyl.
  • R 11 , R 12 , R 13 and R 14 may independently be H, an optionally substituted C 1-3 alkyl, an optionally substituted C 1-3 alkenyl or an optionally substituted C 1-3 alkynyl.
  • R 11 , R 12 , R 13 and R 14 may each be H.
  • the diamine may be 1,6-diaminohexane.
  • the method may comprise contacting the pre-activated substrate with ammonia or the diamine in the presence of a third solvent.
  • the third solvent may be or comprise water.
  • the volumetric ratio of the third solvent to the ammonia may be between 1:10 and 50:1, between 1:5 and 30:1, between 1:2 and 20:1, between 1:1 and 10:1, between 2:1 and 7.5:1, between 3:1 and 5:1 or between 3.5:1 and 4.5:1.
  • the epoxy-activated substrate and ammonia may be contacted at a temperature between -10 and 100°C, between 0 and 90°C, between 10 and 80°C, between 20 and 60°C, between 30 and 50°C or between 35 and 45°C.
  • the epoxy-activated substrate and ammonia may be contacted for at least 1 minute, at least 5 minutes, at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, at least 12 hours or at least 18 hours.
  • the first activated substrate and cyanuric chloride may be contacted for between 1 minute and 4 weeks, between 1 hour and 1 week, between 2 and 72 hours, between 4 and 48 hours, between 6 and 36 hours, between 12 and 24 hours or between 16 and 20 hours.
  • the method may comprise contacting a substrate and a compound of formula (VIII): (VIII) wherein L 6 is an optionally substituted C 1-24 alkylene, an optionally substituted C 2-24 alkenylene or an optionally substituted C 2-24 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is optionally interrupted by one or more heteroatoms; and O R 15 is a reactive leaving group ; to provide the epoxy-activated In embodiments where R 15 is a leaving group, R 15 may be a halogen.
  • R 15 may be chlorine, or iodine. In some embodiments, R 15 is chlorine.
  • the or each heteroatom may be selected from the group consisting of NR 5 , O and S, wherein R 5 is H or an optionally substituted C 1-12 alkyl, an optionally substituted C 1-12 alkenyl or an optionally substituted C 1-12 alkynyl.
  • L 6 may be an optionally substituted C 1-12 alkylene, an optionally substituted C 2-12 alkenylene or an optionally substituted C 2-12 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is optionally interrupted by one or more heteroatoms.
  • L 6 is an optionally substituted C 1-6 alkylene, an optionally substituted C 2-6 alkenylene or an optionally substituted C 2-6 alkynylene, where the backbone of the alkylene, alkenylene or alkynlene is optionally interrupted by one or more heteroatoms.
  • L 6 is an optionally substituted C 1-3 alkylene, an optionally substituted C 2-3 alkenylene or an optionally substituted C 2-3 alkynylene.
  • L 6 is –CH 2 –.
  • the backbone of the alkylene, alkenylene or alkynlene is interrupted by one or more heteroatoms, preferably 2 heteroatoms. The or each heteroatom may be O. Accordingly, L 6 may be –CH 2 -O-(CH 2 ) 4 -O-CH 2 –.
  • the compound of formula (VIII) may be epichlorohydrin or 1,4-butanediol diglycidyl ether.
  • the method may comprise contacting a substrate and a compound of formula (IX): 1 6 wherein R is a reactive leaving group; to provide the allyl-activated substrate.
  • R 16 may be a halogen. Accordingly, R 16 may be chlorine, bromine or iodine. In some embodiments, R 16 is bromine. Accoridngly, the compound of formula (IX) may be allyl bromide.
  • the method may comprise contacting a substrate and an oxidising agent.
  • the oxidising agent may be a periodate, optionally sodium periodate or potassium periodate.
  • the substrate may be as defined in relation to the first aspect.
  • the substrate and the compound of formula (VIII) or (IX) may be contacted in a weight ratio of between 100:1 and 1:2, between 50:1 and 1:1, between 20:1 and 5:2 or between 10:1 and 5:1.
  • the substrate and compound of formula (VIII) or (IX) may be contacted in the presence of a base.
  • the base may be or comprise a hydroxide, a carbonate or an amine.
  • the base may be or comprise sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, diisopropylethylamine, trimethylamine or n- methyl morpholine.
  • the method may comprise contacting the substrate and the compound of formula (VIII) or (IX) in the presence of a fourth solvent.
  • the fourth solvent may be or comprise water.
  • the hydroxide may be present at a concentration of between 0.001 and 50 M, between 0.01 and 20 M, between 0.05 and 10 M, between 0.1 and 5 M, between 0.3 and 3 M, between 0.5 and 2 M, between 0.7 and 1.5 M, between 0.9 and 1.3 M, between 1 and 1.2 M or between 1.05 and 1.15 M.
  • adsorbent of the first aspect to purify a biological product.
  • a method of purifying a biological product comprising contacting an adsorbent with an impure solution comprising the biological product, wherein the adsorbent is as defined in the first aspect, the impure solution comprises one or more impurities and contacting the impure solution with the adsorbent separates the biological product partially or wholly from the one or more impurities to thereby purify the biological product.
  • the use of the fourth aspect may be in adsorption chromatography.
  • the method of the fifth aspect is preferably a method of conducting adsorption chromatography.
  • the method may comprise contacting the adsorbent with the impure solution in a batch process. Accordingly, the method may comprise disposing the adsorbent and the impure solution in a container. The method may comprise disposing the adsorbent and the impure solution in the container for a period of time. The period of time may depend upon a number of factors. Suitable periods of time may be suitably selected by the skilled person. The period of time may be at least 1 minute, at least 5 minutes, at least 10 minutes, at least 15 minutes, at least 20 minutes or at least 25 minutes.
  • Suitable periods of time may be between 1 minute and 1 week, between 5 minutes and 48 hours, between 10 minutes and 24 hours, between 15 minutes and 12 hours, between 20 minutes and 6 hours, between 25 minutes and 2 hours or between 30 minutes and 1 hour.
  • the method may subsequently comprise separating the adsorbent and the impure solution.
  • the method may comprise contacting the adsorbent with the impure solution in a continuous process.
  • the method may comprise disposing the adsorbent in a container and flowing the impure solution through the container.
  • the container may be a column or a filter housing.
  • disposing the adsorbent in the column may comprise: - packing the column with the adsorbent; - equilibrating the column; and - feeding the impure solution through the column.
  • Packing the column with the adsorbent may comprise disposing the adsorbent in the column and causing a packing solution to flow therethrough.
  • Equilibrating the column may comprise causing an equilibration buffer to flow through the column. Suitable packing solutions and equilibration buffers will be known in the art.
  • the biological product may be selected from the group consisting of an amino acid, a peptide, an affimer, a protein, an enzyme, a glycoprotein, a lipopolysaccharide, an antibody or an antigen-binding fragment thereof, an antigen, a nucleic acid, an organic polymer, a virus, a virus related structure, a viral vector, a bacterium, a bacterium related structure, a cell, a cell-related structure, an exosome, an extracellular vesicle and combinations thereof.
  • the biological product may have a molecular weight of at least 1 kDa, at least 10 kDa, at least 25 kDa, at least 50 kDa, at least 75 Da, at least 100 kDa, at least 120 kDa or at least 140 kDa.
  • the biological product may have a molecular weight of between 1 and 10,000 kDa, between 10 and 1,000 kDa, between 25 and 750 kDa, between 50 and 500 kDa, between 75 and 250 kDa, between 100 and 200 kDa, between 120 and 180 kDa or between 140 and 160 kDa.
  • the impure solution may comprise the biological product at a concentration of between 0.001 and 500 mg/mL.
  • the impure solution may comprise the biological product at a concentration of between 0.01 and 250 mg/mL, between 0.1 and 100 mg/mL, between 0.5 and 75 mg/mL, between 1 and 50 mg/mL, between 2 and 20 mg/mL, between 3 and 10 mg/mL, between 4 and 8 mg/mL, between 5 and 6 mg/ml or between 5.25 and 5.75 mg/mL.
  • the impure solution may comprise the biological product at a concentration of between 0.001 and 10 mg/mL, between 0.005 and 7.5 mg/ml or between 0.01 and 5 mg/mL.
  • the impure solution may comprise the biological product at a concentration of between 1 x 10 6 and 1 x 10 20 particles per ml, between 1 x 10 7 and 1 x 10 15 particles per ml, between 1 x 10 8 and 1 x 10 14 particles per ml or between 1 x 10 10 and 1 x 10 13 particles per ml.
  • the biological product is an antibody or antigen-binding fragment thereof.
  • the antibody or antigen-binding fragment thereof may be a polyclonal or monoclonal antibody or antigen-binding fragment thereof.
  • the antibody or antigen- binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.
  • the antibody or antigen-binding fragment thereof may be IgA, IgD, IgE, IgG, and IgM. Preferably, the antibody or antigen-binding fragment thereof is IgG.
  • the antibody or antigen-binding fragment thereof may be monovalent, divalent or polyvalent.
  • Monovalent antibodies are dimers (HL) comprising a heavy (H) chain associated by a disulphide bridge with a light chain (L).
  • the antibody fragment may include an individual heavy or light chain, or a fragment thereof, such as VL, VH and Fd; a monovalent fragment, such as Fv, Fab, and Fab'; a bivalent fragment, such as F(ab') 2 ; a single chain Fv (scFv); or a Fc fragment.
  • the antigen-binding fragment of the antibody may be a single domain antibody (sdAb) (also referred to as a nanobody).
  • sdAb is an antibody fragment consisting of a single monomeric variable antibody domain (referred to as a VHH).
  • the antigen-binding fragment of the antibody may be a single-chain antibody, an intrabody, a peptide (e.g. a bicyclic peptide), or any other type of fragment.
  • the antibody or antigen-binding fragment thereof may have a molecular weight of at least 1 kDa, at least 10 kDa, at least 25 kDa, at least 50 kDa, at least 75 Da, at least 100 kDa, at least 120 kDa or at least 140 kDa.
  • the antibody or antigen-binding fragment thereof may have a molecular weight of between 1 and 10,000 kDa, between 10 and 1,000 kDa, between 25 and 750 kDa, between 50 and 500 kDa, between 75 and 250 kDa, between 100 and 200 kDa, between 120 and 180 kDa or between 140 and 160 kDa.
  • the impure solution may comprise the antibody or antigen-binding fragment thereof at a concentration of between 0.001 and 500 mg/mL, between 0.01 and 250 mg/mL, between 0.1 and 100 mg/mL, between 0.5 and 75 mg/mL, between 1 and 50 mg/mL, between 2 and 20 mg/mL, between 3 and 10 mg/mL, between 4 and 8 mg/mL, between 5 and 6 mg/ml or between 5.25 and 5.75 mg/mL.
  • the biological product is a virus or a viral vector.
  • the virus or viral vector may be or comprise an adenovirus, a retrovirus, a poxvirus, a baculovirus, a herpes simplex virus, an adeno-associated virus, a lentivirus, or an Espirito Santo virus (ESV).
  • the virus or viral vector may be an engineered virus or viral vector.
  • the adenovirus may be an engineered adenovirus
  • the adeno-associated virus may be an engineered adeno-associated virus
  • the lentivirus may be an engineered lentivirus.
  • the adeno-associated virus may be or comprise an AAV1 – AAV9 serotype.
  • the impure solution may comprise the virus or viral vector at a concentration of between 1 x 10 6 and 1 x 10 20 particles per ml, between 1 x 10 7 and 1 x 10 15 particles per ml, between 1 x 10 8 and 1 x 10 14 particles per ml or between 1 x 10 10 and 1 x 10 13 particles per ml.
  • the biological product is a nucleic acid.
  • the nucleic acid may be or comprise DNA, plasmid DNA, doggy-bone DNA, RNA, micro RNA, small interfering RNA, messenger RNA, transfer RNA or antisense RNA.
  • the impure solution may comprise the nucleic acid at a concentration of between 0.001 and 10 mg/mL, between 0.005 and 7.5 mg/ml or between 0.01 and 5 mg/mL.
  • the biological product is a microvesicle, an exosome or an extracellular vesicle.
  • the microvesicle, exosome or extracellular vesicle may be isolated from a eukaryotic cell.
  • the eukaryotic cell may be a HEK293 cell, a stem cell, a dendritic cell, a human amniotic epithelial cell or a chimeric antigen receptor (CAR)-T cell.
  • the stem cell may be a mesenchymal stem cell.
  • the impure solution may have a desired pH.
  • the desired pH may be between 0 and 14 at 20°C, between 2 and 13 at 20°C, between 4 and 12 at 20°C, between 5 and 11 at 20°C, between 6 and 10 at 20°C, between 7 and 9 at 20°C, between 7.5 and 8.5 at 20°C or between 7.75 and 8.25 at 20°C.
  • the method may comprise adjusting the pH of the impure solution comprising the biological product to the desired pH.
  • the impure solution may have a desired osmolality.
  • the osmolality may be between 1 and 50 mS/cm, between 2 and 25 mS/cm, between 3 and 20 mS/cm, between 4 and 17.5 mS/cm or between 5 and 15 mS/cm.
  • the method may comprise separating the biological product, or a solution comprising the biological product, from the adsorbent.
  • the one or more impurities are preferably partially or wholly captured and removed by an adsorbent of the invention.
  • the one or more impurities are partially or wholly adsorbed by the adsorbent.
  • An impurity may be understood to partially adsorbed by the adsorbent if at least 50% of the impurity is adsorbed, more preferably at least 60%, at least 70% or at least 80% of the impurity is adsorbed, and most preferably at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% of the impurity is adsorbed.
  • An impurity may be understood to be adsorbed by the adsorbent if it is no longer present in a solution after it has contacted the adsorbent.
  • the amount of the impurity which has been adsorbed may be calculated by determining the concentration of the impurity in a solution prior to and after contacting the adsorbent and calculating a percentage reduction.
  • the biological product is not adsorbed by the adsorbent.
  • the biological product may be understood to not be adsorbed by the adsorbent if less than 50% of the biological product is adsorbed, more preferably less than 40%, less than 30% or less than 20% of the biological product is adsorbed, and most preferably less than 10%, less than 9%, less than 8%, less than 7%, less than 6% or less than 5% of the biological product is adsorbed.
  • the biological product may be understood to be adsorbed by the adsorbent if it is still present in a solution after it has contacted the adsorbent.
  • the amount of the biological product which has been adsorbed may be calculated by determining the concentration of the biological product in a solution prior to and after contacting the adsorbent and calculating a percentage reduction. Accordingly, the biological product may be understood to flow through the adsorbent, and is thereby purified. It will be appreciated by one skilled in the art that the properties of the impure solution may be adjusted prior to contact with an adsorbent to promote the adsorption of impurities, discourage the adsorption of the biological product and/or maintain the integrity and activity of the biological product.
  • the one or more parameters may include, but are not limited to, pH, ionic strength, osmolality, polarity, temperature, buffer composition, buffer concentration and/or the concentration of the biological product.
  • the method may comprise identifying an optimum state for one or more parameters of the impure solution.
  • the optimum state may be an optimum pH, osmolality, polarity, temperature, buffer composition, buffer concentration and/or concentration of the biological product.
  • Identifying the optimum state of the one or more parameters of the impure solution may comprise providing a plurality of samples of the impure solution wherein a parameter varies between the plurality of samples.
  • the method may comprise contacting the adsorbent with the plurality of samples and measuring a variable.
  • the variable may be the amount of an impurity and/or the amount of the biological product which is adsorbed.
  • the optimum state of the one or more parameters may be understood to be the state of the parameter in the sample which exhibits the most desirable outcome as ascertained by measuring the variable.
  • the most desirable outcome may be the most amount of the impurity adsorbed and/or the least amount of the biological product adsorbed.
  • the method may comprise adjusting one or more parameters of the impure solution to the determined optimum state.
  • the one or more impurities may be selected from the group consisting of an amino acid, a peptide, an affimer, a protein, an enzyme, a glycoprotein, a lipopolysaccharide, an antibody or a fragment thereof, a nucleic acid, an organic polymer, a virus, a virus- related structure, a viral vector, a bacterium, a bacterium-related structure, a cell, a cell-related structure, an exosome, an extracellular vesicle, an endogenous impurity, a process-related impurity, a product-related impurity, fragments thereof and combinations thereof.
  • the one or more impurities may comprise one or more contaminant proteins.
  • the one or more contaminant proteins may be selected from the group consisting of an intracellular protein, an extracellular protein, a host cell protein, a cytosolic protein, an enzyme, a hormone, an antibody, a cytokine, a membrane associated protein, a structural protein, a muscle protein, a neuronal protein, a nucleic acid associated protein, a secreted protein, a transport protein, a plasma protein, an intein, a lectin, a virus associated protein, a viral coat protein, a product-related protein, a process- related protein, fragments, modifications or aggregates thereof and combinations thereof.
  • the contaminant protein may be a host cell protein.
  • the host cell may be a bacterial cell, a plant cell, a fungal cell, an insect cell or an animal cell.
  • the host cell is an animal cell.
  • the host cell is a mammalian cell, optionally a Chinese hamster ovary (CHO) cell or a human embryonic kidney (HEK) cell.
  • the host cell is an insect cell, such as a Spodoptera frugiperda cell (e.g. Sf9 or Sf21).
  • the host cell is a bacterial cell, for instance an E. coli cell.
  • the host cell is a fungal cell.
  • the fungal cell may be a yeast cell, for instance a Pichia pastoris cell or a Saccharomyces cerevisiae cell.
  • the contaminant protein may be an enzyme, e.g. an in vitro transcription enzyme.
  • the host cell may be used in a process to produce the biological product.
  • the contaminant protein may have a weight of less than 10,000 kDa, less than 1,000 kDa, less than 500 kDa, less than 200 kDa, less than 100 kDa, less than 75 kDa or less than 60 kDa.
  • the contaminant protein may have a weight of between 0.1 and 10,000 kDa, between 1 and 1,000 kDa, between 10 and 500 kDa, between 10 and 200 kDa, between 20 and 100 kDa, between 30 and 75 kDa or between 40 and 60 kDa.
  • the one or more impurities may comprise a contaminant antibody and/or a contaminant antibody fragment.
  • the contaminant antibody fragment may be an antigen-binding fragment of an antibody.
  • the biological product is an antibody and the one or more impurities comprise a contaminant antibody fragment, wherein the contaminant antibody fragment is a fragment of the biological product.
  • the contaminant antibody fragment may have a molecular weight of less than 100 kDa, less than 75 kDa, less than 50 KDa, less than 40 kDa or less than 30 kDa.
  • the contaminant antibody fragment may have a molecular weight of between 0.1 and 100 kDa, between 1 and 75 kDa, between 5 and 50 kDa, between 10 and 40 kDa or between 20 and 30 kDa.
  • the one or more impurities may comprise one or more contaminant nucleic acids.
  • the one or more contaminant nucleic acids may be or comprise DNA, plasmid DNA, doggy-bone DNA, RNA, micro RNA, small interfering RNA, messenger RNA, transfer RNA, antisense RNA, an oligonucleotide, one or more fragments thereof and/or combinations thereof.
  • the one or more contaminant nucleic acids may comprise one or more oligonucleotides.
  • the one or more contaminant nucleic acids may comprise one or more double stranded nucleic acid fragments.
  • the impure solution may comprise or be a fermentor broth, a clarified fermentor broth, a filtered fermentor broth, a concentrated fermentor broth, a buffer-exchanged fermentor broth, a cell culture media, a clarified cell culture media, a filtered cell culture media, a concentrated cell culture media, a buffer-exchanged cell culture media, a microbial cell extract, a plant cell or plant tissue extract, a fungal cell or fungal tissue extract, an animal cell or animal tissue extract, or an eluate from a precursor adsorbent such as an affinity chromatography, steric exclusion chromatography (SXC), a thiophilic capture step, a hydrophobic interaction capture step, a multi-mode or mixed- mode capture step and/or an ion exchange capture step.
  • a precursor adsorbent such as an affinity chromatography, steric exclusion chromatography (SXC), a thiophilic capture step, a hydrophobic interaction capture step, a multi-mode or
  • An eluate may be understood to be a solution which comprises the biological product.
  • the eluate may be understood to be obtained from chromatography, wherein the biological product has been adsorbed onto a precursor adsorbent.
  • the eluate may be understood to be a solution which is produced when the biological product is released from the precursor adsorbent.
  • the impure solution may comprise or be the eluate.
  • the method may comprise: - conducting a chromatography or capture step on a feedstock solution comprising the biological product to produce an eluate containing the biological product; and - contacting the adsorbent with the impure solution, wherein the impure solution is or comprises the eluate, and thereby purifying the biological product.
  • the chromatography or capture step may comprise affinity chromatography, steric exclusion chromatography, a thiophilic capture step, a hydrophobic interaction capture step, a mixed-mode or multi-mode capture step or an ion exchange capture step.
  • the impure solution may comprise or be an eluate from a Protein A column.
  • the method may comprise: - contacting a Protein A column with a feedstock solution comprising the target biomolecule to produce an eluate comprising the biological product; and - contacting the adsorbent with the eluate, and thereby purifying the biological product.
  • SXC may be used when the biological product is a virus (for instance AAV) and the eluate may comprise one or more impurities (e.g.
  • the method may comprise: - conducting steric exclusion chromatography on a feedstock solution comprising the biological product to produce an eluate containing the biological product; and - contacting the adsorbent with the eluate, and thereby purifying the biological product.
  • Affinity chromatography may be understood to comprise an affinity interaction capture step.
  • the biological product may be or comprise a nucleic acid, e.g. a single stranded mRNA.
  • the feedstock solution may comprise a buffer.
  • the buffer may be configured to maintain the feedstock solution at a pH between 4 and 11, between 5 and 10 or between 6 and 9 at 20°C.
  • the feedstock solution may have an osmolality between 5- 15 mS/cm.
  • the affinity interaction capture step may comprise a poly adenine affinity interaction.
  • the feedstock solution and/or the eluate may comprise one or more impurities.
  • the one or more impurities may comprise one or more oligonucleotides, one or more proteins (e.g. In Vitro Transcription enzymes), one or more double stranded nucleic acid fragments and/or mixtures thereof.
  • the feedstock solution may be purified using a thiophilic, hydrophobic, and/or ion exchange capture step.
  • the biological product may be or comprise a nucleic acid.
  • from the feedstock solution may be purified using a hydrophobic interaction capture step and the biological product may be or comprise a double stranded plasmid DNA.
  • the feedstock solution may comprise a buffer.
  • the buffer may be configured to maintain the feedstock solution at a pH between 4 and 11, between 5 and 10 or between 6 and 9 at 20°C..
  • the feedstock solution may have an osmolality between 5- 15 mS/cm.
  • the feedstock solution and/or the eluate may comprise one or more impurities.
  • the one or more impurities may comprise one or more (e.g. Host Cell Proteins from E Coli).
  • the method may provide the biological product in a non-bound solution.
  • the non- bound solution may be understood to be the solution obtained from contacting the adsorbent and the impure solution comprising the biological product.
  • the method removes one or more contaminant biomolecules which are present in the impure solution.
  • the non-bound solution may comprise fewer impurities than the impure solution.
  • the method may comprise cleaning and/or sanitising the adsorbent. Cleaning and/or sanitising the adsorbent may comprise contacting the adsorbent with a suitable cleaning solution. Suitable cleaning solutions may be known in the art.
  • the adsorbent may then be used to purify further biological products.
  • EXAMPLE 1 Solid-Phase Synthesis of Bis- isobutylamine Triazine Ligand Adsorbent 1.1 Epoxy-Activation of Agarose Beads Water washed beaded agarose, 6% cross-linked, 90 ⁇ m (Purabead 6HF), 1 kg, was slurried with 675 mL water and 85 mL of 10 M NaOH. Epichlorohydrin, 127 mL, was added and the mixture stirred for 16 hours at 18 °C. The epoxy-activated agarose was washed 10 times with 1 L of water and allowed to drain under gravity.
  • the settled gel was re- suspended in 1 M potassium phosphate (250 mL) and water (250 mL) followed by the addition of 500 mL of acetone before cooling under stirring to approximately 2 °C.
  • Approximately 1.4 molar equivalents of cyanuric chloride with respect to the precursor activation density was dissolved in acetone, then added to the slurried aminated base matrix, followed by incubation at 0 - 4 °C for approximately one hour. After this reaction period, the gel was drained, washed with aqueous acetone solutions of decreasing concentration, then a final wash in water, after which the slurry was settled under gravity. The final product of this reaction is the DCT-activated base matrix.
  • the eluate from this Protein A column was adjusted to pH 8 to provide a feedstock load solution with an IgG concentration of approximately 5.5 mg/mL.
  • the column packed in step 2.1 was loaded with 0.8 mL of the IgG enriched feedstock.
  • a post load wash with 10 CV of equilibration buffer was performed. Both the flow through and post load wash samples were collected and pooled to give a non- bound sample.
  • HCP concentration in the load and non-bound sample was determined using a CHO HCP ELISA kit from Cygnus Technologies.
  • a 96 well micro column plate containing 0.25 mL per column of the product of Example 1 was equilibrated by flushing the columns with 3 x 1.0 mL aliquots of 50mM sodium phosphate, 75 mM NaCl, pH 7.4.
  • the columns were loaded with CHO monoclonal antibody feed at pH 7.5 (1.0 mL per column).
  • the columns were then treated with a post load wash consisting of 4 x 0.75 mL aliquots of equilibration buffer. The flow through from the load and the first two post load washes were collected and pooled to give a non-bound fraction. Following post load wash, the columns were treated with 50 mM sodium citrate, pH 30 elution buffer and the elution fractions collected.
  • Coli periplasmic extract with a capture step using a Capto L affinity column Buffers for the Capto L run were the following: ⁇ Equilibration buffer: 20 mM citrate, 800 mM NaCl, pH 5.0 ⁇ Pre-elution buffer: 20 mM citrate, pH 5.0 ⁇ Elution buffer: 20 mM citrate pH 2.8 ⁇ CIP: 15 mM NaOH The Capto L run proceeded as follows: Equilibration: 5 CV, 3 mL/min (229 cm/h), equilibration buffer.
  • the best binding conditions of those tested were found to be pH 6 at 6 mS/cm conductivity. These conditions demonstrated a reduction in HCP concentration from over 30,000 ppm in the load to approximately 200 ppm in the non-bound fraction.
  • the concentration of Vk in the load and non-bound fractions was determined by UV- Visible spectrophotometry, measuring the absorbance of the solutions at 280 nm. With the optimum conditions described above (pH 6 at 6 mS/cm conductivity), the concentration of Vk in the non-bound fraction compared to the load concentration was greater than 80% indicating little loss due to binding of the target Vk.
  • EXAMPLE 6 Solid-Phase Synthesis of Bis-cyclohexylamine Triazine Ligand Adsorbent
  • a dichlorotriazine (DCT) activated substrate was prepared as described in Example 1 up to and including Step 1.3. Amination of DCT activated substrate with cyclohexylamine
  • the DCT activated substrate prepared in Example 1 Step 1.3 was slurried in approximately 1 L of water with 25 mL of cyclohexylamine. The slurry was heated at 60 °C with stirring for at least 6 hours before draining and washing 10 times with 1 L of water.
  • the product from this series of synthesis steps is a chromatographic material containing a ligand which binds host cell proteins, as demonstrated in Example 7.
  • EXAMPLE 7 Use of product of Example 6 for purification of mAb from CHO feedstock.
  • 7.1 Chromatography column packing with product of Example 6 A 5 mm internal diameter column, 1.0 mL volume was packed with the product of Example 6 in 0.1 M NaCl at 2 mL/min (600 cm/h) for 10 column volumes (CV). This yielded a column with 5.0 cm bed height.
  • the feedstock used for this example was an IgG enriched CHO lysate initially purified with a capture step using a Protein A affinity column. The eluate from this Protein A column was adjusted to pH 8 to provide a feedstock load solution with an IgG concentration of approximately 5.5 mg/mL.
  • step 7.2 After equilibration in 10 CV of 25 mM sodium citrate, 25 mM Tris base pH 8.0, the column packed in step 7.2 was loaded with 10 mL of the IgG enriched feedstock. Following this, a post load wash with 10 CV of equilibration buffer was performed. Both the flow through and post load wash samples were collected and pooled to give a non- bound sample. 7.4 Testing non-bound purified sample for IgG yield and HCP clearance. HCP concentration in the load and non-bound sample was determined using a CHO HCP ELISA kit from Cygnus Technologies. This demonstrated a reduction in HCP concentration from over 880 ppm in the load to approximately 460 ppm in the non- bound fraction.
  • the concentration of IgG in the load and non-bound fractions was determined by UV-Visible spectrophotometry, measuring the absorbance of the solutions at 280 nm.
  • the concentration of IgG in the non-bound fraction compared to the load concentration was greater than 95% indicating negligible loss due to binding of the target IgG.
  • this adsorbent may be used to remove contaminants from other expression systems including but not limited to Escherichia coli, Pichia pastoris, Saccharomyces cerevisiae, Spodoptera frugiperda (Sf9 and Sf21) and HEK293 cells.
  • ADVANTAGES ⁇ In the application of IgG purification from a CHO expression system, the product has been demonstrated to selectively bind light chain IgG as well as HCP whilst maintaining high IgG yields. ⁇ The product retains functionality at relatively high conductivity load conditions compared to IEX polishing steps which would require dilution.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgation concerne un procédé de purification d'un produit biologique. Le procédé comprend la mise en contact d'un adsorbant avec une solution impure comprenant le produit biologique. L'adsorbant comprend la formule (I). La solution impure comprend une ou plusieurs impuretés. La mise en contact de la solution impure avec l'adsorbant sépare le produit biologique partiellement ou entièrement de la ou des impuretés pour ainsi purifier le produit biologique en raison de la ou des impuretés partiellement ou totalement adsorbées par l'adsorbant et moins de 50 % du produit biologique étant adsorbé par l'adsorbant. La divulgation concerne également un adsorbant ayant la formule (I), des composés intermédiaires de formules (II) et (III) qui peuvent être utilisés pour produire l'adsorbant et un procédé de production de l'adsorbant.
EP23825080.7A 2022-12-06 2023-12-06 Adsorbant et ses procédés de fabrication et d'utilisation Pending EP4630158A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2218303.2A GB202218303D0 (en) 2022-12-06 2022-12-06 Adsorbent and methods of manufacturing and using the same
PCT/GB2023/053143 WO2024121553A1 (fr) 2022-12-06 2023-12-06 Adsorbant et ses procédés de fabrication et d'utilisation

Publications (1)

Publication Number Publication Date
EP4630158A1 true EP4630158A1 (fr) 2025-10-15

Family

ID=84926578

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23825080.7A Pending EP4630158A1 (fr) 2022-12-06 2023-12-06 Adsorbant et ses procédés de fabrication et d'utilisation

Country Status (6)

Country Link
EP (1) EP4630158A1 (fr)
JP (1) JP2025540236A (fr)
KR (1) KR20250114554A (fr)
CN (1) CN120583992A (fr)
GB (1) GB202218303D0 (fr)
WO (1) WO2024121553A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224446D0 (en) * 2002-10-21 2002-11-27 Univ Cambridge Tech Affinity adsorbents for immunoglobulins

Also Published As

Publication number Publication date
WO2024121553A1 (fr) 2024-06-13
JP2025540236A (ja) 2025-12-11
KR20250114554A (ko) 2025-07-29
CN120583992A (zh) 2025-09-02
GB202218303D0 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
KR101243425B1 (ko) 항체의 정제 방법
US9556258B2 (en) Purification of fusion proteins
KR101921552B1 (ko) 사전 세정 단계를 이용하는 면역글로불린 정제
US9346879B2 (en) Protein purification methods to reduce acidic species
US20140288278A1 (en) Chromatography process for resolving heterogeneous antibody aggregates
EP2855504B1 (fr) Purification chromatographique de préparations d'immunoglobuline g comportant des particules présentant des fonctionnalités multimodales
CN1146730A (zh) 抗体纯化
JP2010209068A (ja) 小モジュラー免疫薬タンパク質を精製する方法
CN105121469A (zh) 用于增加蛋白质的焦谷氨酸形成的方法
KR20210021542A (ko) 크로마토그래피를 사용하여 단백질을 정제하는 방법
US20240376209A1 (en) Method To Control High Molecular Weight Aggregates In An Antibody Composition
WO2024121553A1 (fr) Adsorbant et ses procédés de fabrication et d'utilisation
CA2906808A1 (fr) Purification analytique a base d'affinite de produits biotherapeutiques pour la surveillance de bioprocede
AU2012269240B2 (en) Single unit chromatography antibody purification
CN111886245B (zh) 分离方法
TW202342522A (zh) 臨床人類ｉｇｇ產品之親和層析生產
TW202535904A (zh) 從製程中上游細胞培養材料中快速純化單株抗體
AU2024362809A1 (en) Rapid purification of monoclonal antibody from in-process upstream cell culture material
HK40096315A (zh) 通过混合模式色谱纯化抗体

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)